Press Releases :: Ligand Pharmaceuticals Incorporated (LGND)

Press Releases

Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP

April 7, 2016

Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics

March 28, 2016

Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection

March 15, 2016

Ligand Reports Fourth Quarter and Full Year 2015 Financial Results

February 10, 2016

Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics

February 2, 2016

Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th

January 22, 2016

Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions

January 13, 2016

Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock

December 17, 2015

RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs

December 8, 2015

Ligand Provides Highlights from Today’s Analyst Day Event

November 18, 2015